Vir Biotechnology, Inc. (VIR)
| Market Cap | 1.07B |
| Revenue (ttm) | 86.18M |
| Net Income (ttm) | -615.06M |
| Shares Out | 135.03M |
| EPS (ttm) | -4.59 |
| PE Ratio | n/a |
| Forward PE | 4.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,051,959 |
| Open | 7.95 |
| Previous Close | 7.96 |
| Day's Range | 7.76 - 8.21 |
| 52-Week Range | 7.72 - 27.48 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 33.29 (+318.74%) |
| Earnings Date | May 2, 2024 |
About VIR
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of in... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for VIR stock is "Buy." The 12-month stock price forecast is $33.29, which is an increase of 318.74% from the latest price.
News
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D.
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Direc...
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 202...
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #HepCantWait--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of...
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR--Vir Biotechnology to participate in upcoming March investor healthcare conferences.
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023. “Vi...
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR--Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024.
20 favorite small-cap stocks for 2024 among Wall Street analysts
The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized co...
Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR--Vir Biotechnology makes strategic changes to focus capital allocation on programs with the highest potential for patient impact and value creation.
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #JPM2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief Executive Officer, will present at the J...
Why these stocks could lose money even if the market gains
According to a study published this summer in The Review of Financial Studies, these vulnerable stocks are the ones that are most difficult to borrow and then sell short.
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD's The Liver Meeting® 2023
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #HBV--Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD's The Liver Meeting® 2023.
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD's The Liver Meeting® 2023
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #HBV--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact...
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #Fast500--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first for the second year in a row on the 2023 Deloitte Technology Fast 500™, a list o...
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #TeamVir--Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results.
Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer
SAN FRANCISCO--(BUSINESS WIRE)---- $VIR #TeamVir--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Offic...
Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
SAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Vir's Executive Vice President, Chief Medical Officer and Interim He...
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD's The Liver Meeting® 2023
Eight abstracts highlighting new data from Vir's chronic hepatitis B and chronic hepatitis delta programs have been accepted for presentation at AASLD.
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter en...
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
– New investment of approximately $50 million from Biomedical Advanced Research and Development Authority includes $40 million in Project NextGen funds – – Contract expands existing support for the de...
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Vir Biotechn...
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine –
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Vir Biotechnolo...
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
First patient dosed in a PEG-IFN -α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in enriching pa...
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vir Biotechnology, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Vir Biotechnolog...
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
– Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs on track for Q4 2023 –